Binding of 131I-Labeled Tissue-Type Plasminogen Activator on De-Endothelialized Lesions in Rabbits

Tissue-type plasminogen activator (t-PA) which has a high affinity for fibrin in the clot, was labeled with 131I by the iodogen method, and its binding to de-endothelialized lesions in the rabbit was measured to assess the detectability of thrombi. The de-endothelialized lesion was induced in the abdominal aorta with a Fogarty 4F balloon catheter. Two hours after the de-endothelialization, 131I-labeled t-PA (125 ± 46 μCi) was injected intravenously. The initial half-life of the agent in blood (n = 12) was 2.9 ± 0.4 min. The degree of binding of 131I-labeled t-PA to the de-endothelialized lesion was evaluated at 15 min (n = 6) or at 30 min (n = 6) after injection of the agent. In spite of the retention of the biochemical properties of 131I-labeled t-PA and the presence of fibrin deposition at the de-endothelialized lesion, the binding of t-PA to the lesion was not sufficiently strong. Lesion-to-control ratios (cpm/g/cpm/g) were 1.65 ± 0.40 (at 15 min) and 1.39 ± 1.31 (at 30 min), and lesion-to-blood ratios were 1.39 ± 0.32 (at 15 min) and 1.36 ± 0.23 (at 30 min). These results suggest that radiolabeled t-PA may be inappropriate as a radiopharmaceutical for the scintigraphic detection of a pre-existing thrombotic lesion. Zusammenfassung Gewebespezifischer Plasminogen-Aktivator (t-PA), der im Gerinnsel eine hohe Affinität zu Fibrin hat, wurde mit Hilfe der Jodogen-Methode mit 131J markiert. Bei der Ratte wurde seine Anreicherung in einer Endothelläsion gemessen, um herauszufinden, inwieweit Thromben damit nachweisbar sind. Die Desendothelialisierung dér Bauchaorta in dér Ratte wurde durch einen Fogarty-4F-Ballon-Ka-theter vorgenommen. Zwei Stunden nach der Desendothelialisation wurde 131J-markiertes t-PA (125 ± 46 (μCi, Mittel ± Standardabweichung) intravenös injiziert. Die initiale Halbwertszeit der Substanz im Blut (n = 12) lag bei 2,9 ± 0,4 min. Das Ausmaß der Anreicherung des 131J-markierten t-PA in der Endothelverletzung wurde 15 min (n = 6) oder 30 min (n = 6) nach Gabe dieser Substanz ermittelt. Obwohl die biochemischen Eigenschaften des 131J-markierten t-PA unverändert blieben und die Fibrinablagerung in der Endothelläsion vorhanden war, war die Bindung des 131J-markierten t-PA an der Läsion nicht ausreichend, wie im folgenden gezeigt wird. Die Verhältnisse Läsion zu Kontrolle (cpm/g/cpm/ g) waren 1,65 ± 0.40 (nach 15 min) und 1,39 ± 1,31 (nach 30 min), und die Verhältnisse Läsion zu Blut ± 0,32 (nach 15 min) und 1,36 ± 0,23 (nach 30 min). Aufgrund dieser Ergebnisse scheint radioaktiv markiertes t-PA als Radiopharmazeutikum für den szintigraphischen Nachweis einer vorbestehenden thrombotischen Läsion nicht geeignet zu sein.

[1]  K. Yamamoto,et al.  Radioimmunoimaging of experimental thrombi in dogs using technetium-99m-labeled monoclonal antibody fragments reactive with human platelets. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  H. Atkins,et al.  Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Paramo,et al.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. , 1985, The Journal of clinical investigation.

[4]  P. Wallén,et al.  In vivo metabolism of human tissue-type plasminogen activator. , 2009, Scandinavian journal of haematology.

[5]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[6]  D. Collen,et al.  Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species , 1984, Thrombosis and Haemostasis.

[7]  K. Kimura,et al.  Platelet accumulation in carotid atherosclerotic lesions: semiquantitative analysis with indium-111 platelets and technetium-99m human serum albumin. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  W. Totty,et al.  Aspirin inhibition of platelet deposition at angioplasty sites: demonstration by platelet scintigraphy. , 1984, Radiology.

[9]  C. McCollum,et al.  Indium-labeled platelet uptake in rejecting renal transplants. , 1983, Surgery, gynecology & obstetrics.

[10]  B. Wiman,et al.  Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. , 1983, Thrombosis research.

[11]  E. Mullaart,et al.  A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma , 1982, Thrombosis and Haemostasis.

[12]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[13]  C. Korninger,et al.  Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits , 1981, Thrombosis and Haemostasis.

[14]  M. Thakur,et al.  Imaging Experimental Coronary Artery Thrombosis with Indium-111 Platelets , 1979, Circulation.

[15]  K. Moser,et al.  Clinically suspected deep venous thrombosis of the lower extremities. A comparison of venography, impedance plethysmography, and radiolabeled fibrinogen. , 1977, JAMA.

[16]  E. Pollak,et al.  Thrombosis detection by radionuclide particle (MAA) entrapment: correlation with fibrinogen uptake and venography. , 1974, Radiology.

[17]  M. Scully,et al.  Binding of Iodinated Proteins to Forming and Preformed Thrombi , 1973 .

[18]  N. Greyson,et al.  Observations on the use of 99mTc albumin macroaggregates for detection of thrombophlebitis. , 1970, Radiology.